Company Filing History:
1 out of 832,761 Years Active: 1999
Title: Carol S Enderlin: Innovator in Antifungal Research
Introduction
Carol S Enderlin is a notable inventor based in Denver, CO (US). She has made significant contributions to the field of antifungal drug development. Her work focuses on the synthesis of (1,3).beta.-linked glucan, which is crucial for fungal wall assembly and infection.
Latest Patents
Enderlin holds 1 patent related to (1,3).beta.-glucan synthase genes and the inducible inhibition of fungal - A (1,3).beta.-glucan synthase mutants. This invention is particularly important as it targets a key step in fungal growth, making it a promising avenue for developing new antifungal antibiotics. The cloning of a (1,3).beta.-glucan synthase gene has allowed for the establishment of its cDNA sequence and polypeptide amino acid sequence.
Career Highlights
Throughout her career, Enderlin has focused on innovative solutions to combat fungal infections. Her research has paved the way for advancements in antifungal therapies, which are critical in treating various fungal diseases.
Collaborations
Enderlin has collaborated with Claude P Selitrennikoff, enhancing her research efforts and contributing to the scientific community's understanding of antifungal mechanisms.
Conclusion
Carol S Enderlin's work exemplifies the importance of innovation in the fight against fungal infections. Her contributions to the field are invaluable and continue to influence antifungal drug development.